Skip To Main Content
Madison H. Milaszewski on Muck Rack

Madison H. Milaszewski

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Madison H. Milaszewski’s profile

Articles by Madison H. Milaszewski

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

|
By Ben George, Harshabad Singh, Craig E. Devoe, Vincent C. H. Chung, Peter J. Hosein, Andrew Hendifar, Jennifer Valerin, Tanios S Bekaii-Saab, Manuel Hidalgo, Pashtoon M. Kasi, Alexis Leal, Meredith S. Pelster, Naomi Fei, Colin D Weekes, Mark O’Hara, Thomas George, Jonathan Mizrahi, Suresh Nair, Martin J. Maiers, Thian Kheoh, Gianni Amato, Julia Snyder, Xavier Cabana-Puig, James Perry, Lisa Mcneil, Peter Demuth, Christopher Haqq, Shubham Pant, Zev A. Wainberg, Eileen M. O’Reilly, Syed M. Kazmi, Jino Xavier, Madison H. Milaszewski, Esther Welkowsky
| Nature Verified
Abstract Camupepimut (ELI-002 7P) drives mutated KRAS (mKRAS)-specific T cell responses that correlated with disease-free survival (DFS) and overall survival (OS) in patients with mKRAS pancreatic adenocarcinoma (PDAC) in the phase 1 AMPLIFY-201 trial. In the phase 2 AMPLIFY-7P trial, patients with stage I-III KRAS-mutated PDAC without recurrence within 6 months of standard therapy were randomized 2:1 to camupepimut (n = 96) or standard-of-care/observation (n = 48).
Open in Who Shared Issue with article?
Show More